Nabil Tabish: TEG Reveals the True Effect of Heparin During ECMO
Nabil Tabish, Regional Medical Director at Kaiser Permanente, shared a post on LinkedIn:
”This infographic visually tells the story of a patient on ECMO; we discussed, focusing on the critical difference between measuring Unfractionated heparin’s chemical concentration versus its actual, functional effect. It contrasts two very different diagnostic views of the same patient:
The Misleading Standard Labs: On one side, the plasma-based labs (the anti-Xa level of 0.38 IU/mL and PTT of 47 seconds) falsely suggested the patient was only mildly anticoagulated. These isolated tests can be highly misleading in complex scenarios like ECMO where factors like Antithrombin III are depleted.
The Accurate TEG 6s Assessment: On the other side, the design highlights the TEG 6s whole-blood functional assessment. It illustrates the stark contrast between the patient’s severely prolonged CK (Citrated Kaolin) R-time of greater than 17 minutes and their completely normal CKH (Citrated Kaolin with Heparinase) R–time of 6.9 minutes.
By visually showing how neutralizing the heparin in the CKH channel instantly corrects the delayed clotting time, there is mechanical proof that the heparin profoundly anticoagulanting the patient.
Ultimately, the piece visually reinforces the manufacturer’s guidance that diagnostic results should always be evaluated and functional assays play a superior role in complex clinical patients with a refined balance between thrombosis and anticoagulation.”
Stay updated with Hemostasis Today.
-
Aug 23, 2026, 16:09Felice Gragnano: New Publication on Aspirin Discontinuation After PCI for Acute Coronary Syndromes
-
Aug 23, 2026, 16:06Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia
-
Aug 23, 2026, 10:10Sthanu Subramanian: Empagliflozin and a Rise in Hematocrit
-
Aug 23, 2026, 16:03Balaji Balagani: Major Causes of Sudden Cardiac Death in Children
-
Aug 23, 2026, 16:02Bartosz Hudzik: What’s Hot at ESC Congress 2026
-
Aug 23, 2026, 16:01Jim Hoffman: NETs in STEMI and Their Association With PCI and Antithrombotic Treatments
-
Aug 23, 2026, 16:01Luis Oliverio Ambriz Garcia: Key Insights Into Myeloproliferative Neoplasms From the 2026 NEJM Review
-
Aug 23, 2026, 15:58Howard Smith: Automated MR Imaging Aids New Stroke Therapy Development
-
Aug 23, 2026, 15:58Nilesh Jethwa: Top Reported Adverse Reactions to Apixaban